Policaptil Gel Retard + metformin

Policaptil Gel Retard + metformin is a combination therapy consisting of Policaptil Gel Retard, a macromolecular complex based on polysaccharides (natural fiber-based molecule), and metformin, a well-established oral antihyperglycemic agent. Policaptil Gel Retard acts by slowing the absorption of carbohydrates and fats in the gastrointestinal tract, thereby reducing postprandial glucose and lipid levels. Metformin primarily works by decreasing hepatic glucose production and improving insulin sensitivity. The combination is investigated for synergistic effects on weight loss, glycemic control, insulin resistance reduction, and improvement in metabolic syndrome parameters. Clinical studies suggest that this combination may be more effective than either agent alone for improving insulin sensitivity and reducing body mass index in obese adolescents or adults at risk for type 2 diabetes mellitus (T2DM) or with metabolic syndrome[2][4]. Both agents have distinct mechanisms—Policaptil Gel Retard modulates nutrient absorption while metformin targets hepatic glucose output—potentially leading to additive or synergistic benefits.